For: | Yang HH, Huang Y, Zhou XC, Wang RN. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis. World J Clin Cases 2022; 10(18): 6091-6104 [PMID: 35949827 DOI: 10.12998/wjcc.v10.i18.6091] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v10/i18/6091.htm |
Number | Citing Articles |
1 |
Ahmed Salman, Mohamed A Salman, Ahmed Elewa, Asmaa M Awwad. Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis. Cureus 2024; doi: 10.7759/cureus.61547
|
2 |
Nariman Hossein-Javaheri, Michael Youssef, Yaanu Jeyakumar, Vivian Huang, Parul Tandon. The Management of Inflammatory Bowel Disease during Reproductive Years: An Updated Narrative Review. Reproductive Medicine 2023; 4(3): 180 doi: 10.3390/reprodmed4030017
|
3 |
Martina Tallarico, Caterina Palleria, Livia Ruffolo, Rocco Spagnuolo, Maria Diana Naturale, Adele Emanuela De Francesco, Caterina De Sarro, Rossella Romeo, Rita Citraro, Patrizia Doldo, Ludovico Abenavoli, Luca Gallelli, Francesco Luzza, Antonio Leo, Giovambattista De Sarro. Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study. Pharmaceutics 2022; 14(11): 2449 doi: 10.3390/pharmaceutics14112449
|
4 |
Mahmoud E. Kamal, Rehab H. Werida, Mahasen A. Radwan, Safaa R. Askar, Gamal A. Omran, Marwa A. El-Mohamdy, Radwa S. Hagag. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology 2024; doi: 10.1007/s10787-024-01508-w
|